|
[1] WHO. Global health sector strategy on viral hepatitis 2016-2021[M/OL]. Geneva:World Health Organization,2016. https://www. Who. int/hepatitis/strategy 2016-2021/ghsshep/en/．
|
|
[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 Version)[J].J Clin Hepatol,2019,35(12):2670-2686.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2019年版)[J]．临床肝胆病杂志，2019,35(12):2670-2686.
|
|
[3] ALTHABE F,CHOMBA E,TSHEFU AK,et al. A multifaceted intervention to improve syphilis screening and treatment in pregnant women in Kinshasa,Democratic Republic of the Congo and in Lusaka,Zambia:A cluster randomised controlled trial[J]. Lancet Glob Health,2019,7(5):e655-e663.
|
|
[4] COWARD S,LEGGETT L,KAPLAN GG,et al. Cost-effectiveness of screening for hepatitis C virus:A systematic review of economic evaluations[J]. BMJ Open, 2016, 6(9):e011821.
|
|
[5] Prevalence of HIV and HCV infection in penitentiary institutions[EB/OL]. http://www. institucionpenitenciaria. es/web/export/sites/default/datos/descargables/saludpublica/Prevalencia(2015).
|
|
[6] LLERENA S,COBO C,ALVAREZ S,et al. A program of testing and treat intended to eliminate hepatitis C in a prison:The JAILFREE-C study[J]. Hepatology,2016,64:460A.
|
|
[7] DALGIC OO,SAMUR S,SPAULDING AC,et al. Improved health outcomes from hepatitis C treatment scale-up in Spain’s prisons:A cost-effectiveness study[J]. Sci Rep,2019,9(1):16849.
|
|
[8] TASILLO A,EFTEKHARI YAZDI G,NOLEN S,et al. Shortterm effects and long-term cost-effectiveness of universal hepatitis C testing in prenatal care[J]. Obstet Gynecol,2019,133(2):289-300.
|
|
[9] ASSOUMOU SA,TASILLO A,LEFF JA,et al. Cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings[J]. Clin Infect Dis,2018,66(3):376-384.
|
|
[10] HILL A,ANDREW B,MELISSA G,et al. Generic treatments for HIV,HBV,HCV,TB could be mass produced for <90per patient[J]. J Int Aids Soc,2017,20:44-45.
|
|
[11] HEATH K. Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C[J]. Clinicoecon Outcomes Res,2018,10:539-550.
|
|
[12] CHAILLON A,MEHTA SR,HOENIGL M,et al. Cost-effectiveness and budgetary impact of HCV treatment with directacting antivirals in India including the risk of reinfection[J].PLo S One,2019,14(6):e0217964.
|
|
[13] CIPRIANO LE,GOLDHABER-FIEBERT JD. Population health and cost-effectiveness implications of a “Treat All”recommendation for HCV:A review of the model-based evidence[J]. MDM Policy Pract,2018,3(1):2381468318776634.
|
|
[14] KRAUTH C,ROSSOL S,ORTSTER G,et al. Elimination of hepatitis C virus in Germany:Modelling the cost-effectiveness of HCV screening strategies[J]. BMC Infect Dis,2019,19(1):1019.
|
|
[15] WHO. Guidelines on hepatitis B and C testing[M]. Geneva:World Health Organization,2017.
|
|
[16] HILL AM,NATH S,SIMMONS B. The road to elimination of hepatitis C:Analysis of cures versus new infections in 91countries[J]. J Virus Erad,2017,3(3):117-123.
|
|
[17] RINGELHAN M,MCKEATING JA,PROTZER U. Viral hepatitis and liver cancer[J]. Philos Trans R Soc Lond B Biol Sci,2017,372(1732):20160274.
|
|
[18] SMITH BD,MORGAN RL,BECKETT GA,et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965[J]. MMWR Recomm Rep,2012,61(RR-4):1-32.
|
|
[19] SMITH BD,MORGAN RL,BECKETT GA,et al. Hepatitis C virus testing of persons born during 1945-1965:Recommendations from the centers for disease control and prevention[J].Ann Intern Med,2012,157(11):817-822.
|
|
[20] WARD JW. The epidemiology of chronic hepatitis C and onetime hepatitis C virus testing of persons born during 1945 to 1965in the United States[J]. Clin Liver Dis,2013,17(1):1-11.
|
|
[21] MANJELIEVSKAIA J,BROWN D,SHRIVER CD,et al. CDC screening recommendation for baby boomers and hepatitis C virus testing in the US military health system[J]. Public Health Rep,2017,132(5):579-584.
|
|
[22] WARD JW. The hidden epidemic of hepatitis C virus infection in the United States:Occult transmission and burden of disease[J]. Top Antivir Med,2013,21(1):15-19.
|
|
[23] GREBELY J,BILODEAU M,FELD JJ,et al. The second Canadian symposium on hepatitis C virus:A call to action[J].Can J Gastroenterol,2013,27(11):627-632.
|
|
[24] GRAD R,THOMBS BD,TONELLI M,et al. Recommendations on hepatitis C screening for adults[J]. CMAJ,2017,189(16):e594-e604.
|
|
[25] TRUBNIKOV M,YAN P,NJIHIA J,et al. Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada(1991-2010):An age-period-cohort analysis[J]. Cmaj Open,2014,2(4):e281-e287.
|
|
[26] GOMAA A,ALLAM N,ELSHARKAWY A,et al. Hepatitis C infection in Egypt:Prevalence,impact and management strategies[J]. Hepat Med,2017,9:17-25.
|
|
[27] RICHMOND JA,WALLACE J. Implementation of hepatitis C cure in Australia:One year on[J]. J Virus Erad,2018,4(2):115-117.
|
|
[28] China National Narcotics Control Committee. Release of 2018China Drug Situation Report:Overall better but still complex situation in drug control[J]. Shanghai Chem Industry,2019,44(7):45.(in Chinese)国家禁毒委员会．2018年中国毒品形势报告发布:禁毒态势总体趋好、面临形势依然复杂[J]．上海化工，2019,44(7):45.
|
|
[29] ZHUANG H. Hepatitis C infection in China:Current status and measures for prevention and treatment[M]. Beijing:People’s Medical Publishing House,2017.(in Chinese)庄辉．中国丙型肝炎感染现状及防治对策研究报告[M]．北京:人民卫生出版社，2017.
|
|
[30] TAO LP,FU ZQ,LI ML,et al. Hepatitis C virus infection and related influencing factors in a drug rehabilitation center in Jiangsu Province,China[J]. Acta Univ Med Nanjing(Natural Sci),2019,39(10):1464-1467,1493.(in Chinese)陶礼平，符祖强，李茂林，等．江苏省某戒毒所丙型肝炎病毒感染情况及影响因素分析[J]．南京医科大学学报(自然科学版)，2019,39(10):1464-1467,1493.
|
|
[31] CONG Y,WANG XG,YE L,et al. Analysis of sexually transmitted diseases infection and its influencing factors among isolated drug users in Zhejiang Province[J]. Chin J Health Lab Tec,2020,30(2):252-254,257.(in Chinese)丛迎，王晓光，叶灵，等．浙江省强制隔离戒毒人群性传播疾病感染状况及影响因素分析[J]．中国卫生检验杂志，2020,30(2):252-254,257.
|
|
[32] HU AY,DENG JH,DONG XY,et al. HIV and HCV infection status and influence factors among drug addicts under compulsory rehabilitation in Baoshan city of Yunnan province[J].Chin J AIDS STD,2019,25(11):1113-1116.(in Chinese)胡安艳，邓家欢，董贤雅，等．保山市强制戒毒人员HIV和HCV感染状况及影响因素[J]．中国艾滋病性病，2019,25(11):1113-1116.
|
|
[33] van de VEN N,FORTUNAK J,SIMMONS B,et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus[J]. Hepatology,2015,61(4):1174-1182.
|
|
[34] National Health and Family Planning Commission of the People’s Republic of China. Screening and management of viral hepatitis C[J]. Infect Dis Info,2015,1:1-2.(in Chinese)中华人民共和国国家卫生和计划生育委员会．丙型病毒性肝炎筛查及管理[J]．传染病信息，2015,1:1-2.
|
|
[35] CUI MJ. A case-control study of risk factors for HCV infection[D]. Beijing:Chinese Center for Disease Control and Prevention,2014.(in Chinese)崔妹娟．HCV感染危险因素的病例对照研究[D]．北京:中国疾病预防控制中心，2014.
|
|
[36] National Health and Family Planning Commission,National Development and Reform Commission, Ministry of Education,et al. Action plan for the prevention and treatment of viral hepatitis in China(2017-2020)[J]. Chin J Viral Dis,2018,8(1):1-5.(in Chinese)国家卫生计生委，国家发展改革委，教育部，等．中国病毒性肝炎防治规划(2017-2020年)[J]．中国病毒病杂志，2018,8(1):1-5.
|
|
[37] LIU L,XU H,HU Y,et al. Hepatitis C screening in hospitals:Find the missing patients[J]. Virol J,2019,16(1):47.
|
|
[38] LI R. Construction plan for national production bases of genuine medicinal materials(2018-2025)jointly issued by Ministry of Agriculture and Rural Affairs,National Medical Products Administration,and State Administration of Traditional Chinese Medicine[J]. J Tradit Chin Med Manage,2018,26(24):inside back cover.(in Chinese)李芮．三部委联合印发《全国道地药材生产基地建设规划(2018-2025年)》[J]．中医药管理杂志，2018,26(24):封3.
|
|
[39] Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015:A modelling study[J]. Lancet Gastroenterol Hepatol,2017,2(3):161-176.
|
|
[40] TANG Y,SUN Q,GU CH,et al. Sentinel surveillance of HIV,hepatitis C and syphilis infections[J]. J Diagn Concepts Pract,2013,12(3):352-354.(in Chinese)汤琰，孙乔，顾春华，等．哨点监测人群中人类免疫缺陷病毒、梅毒、HCV感染的检测结果分析[J]．诊断学理论与实践，2013,12(3):352-354.
|
|
[41] Chinese Center for Disease Control and Prevention. Ministry of Health issued the epidemic situation of notifiable infectious diseases in 2008 and January 2009 in China[R/OL].[2009-02-10]http://www. nhc. gov. cn/jkj/s3578/201304/c9244b1ae3ad48faa8181b87b8caffd5. shtml.(in Chinese)中国疾病预防控制中心．卫生部公布2009年1月及2008年度全国法定报告传染病疫情[R/OL].[2009-02-10] http://www. nhc. gov. cn/jkj/s3578/201304/c9244b1ae3ad48faa8181b87b8caffd5. shtml.
|
|
[42] Chinese Center for Disease Control and Prevention. An overview of the epidemic situation of notifiable infectious diseases in China,2018[R/OL].[2019-04-24] http://www. nhc.gov. cn/jkj/s3578/201904/050427ff32704a5db64f4ae1f6d57c6c.shtml.(in Chinese)中国疾病预防控制中心．2018年全国法定传染病疫情概况[R/OL].[2019-04-24]. http://www. nhc. gov. cn/jkj/s3578/201904/050427ff32704a5db64f4ae1f6d57c6c. shtml.
|
DownLoad: